SK287112B6 - Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie - Google Patents

Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie Download PDF

Info

Publication number
SK287112B6
SK287112B6 SK954-2001A SK9542001A SK287112B6 SK 287112 B6 SK287112 B6 SK 287112B6 SK 9542001 A SK9542001 A SK 9542001A SK 287112 B6 SK287112 B6 SK 287112B6
Authority
SK
Slovakia
Prior art keywords
alkyl
carbon atoms
group
irm
cervical
Prior art date
Application number
SK954-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK9542001A3 (en
Inventor
Kenneth Phares
Jane Z. Li
Michael J. Jozwiakowski
Richard L. Miller
Raymond D. Skwierczynski
Terri F. Busch
Original Assignee
3M Innovative Properties Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Company filed Critical 3M Innovative Properties Company
Publication of SK9542001A3 publication Critical patent/SK9542001A3/sk
Publication of SK287112B6 publication Critical patent/SK287112B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK954-2001A 1999-01-08 2000-01-07 Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie SK287112B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11525399P 1999-01-08 1999-01-08
PCT/US2000/000370 WO2000040228A2 (fr) 1999-01-08 2000-01-07 Formulations et procedes utilises pour le traitement des etats pathologiques des muqueuses au moyen d'un modificateur de la reponse immunitaire

Publications (2)

Publication Number Publication Date
SK9542001A3 SK9542001A3 (en) 2001-12-03
SK287112B6 true SK287112B6 (sk) 2009-12-07

Family

ID=22360189

Family Applications (1)

Application Number Title Priority Date Filing Date
SK954-2001A SK287112B6 (sk) 1999-01-08 2000-01-07 Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie

Country Status (21)

Country Link
US (1) US6245776B1 (fr)
EP (1) EP1140091B1 (fr)
JP (1) JP2002534377A (fr)
KR (1) KR20010101420A (fr)
CN (1) CN1555264A (fr)
AT (1) ATE304852T1 (fr)
AU (1) AU776654B2 (fr)
BR (1) BR0007435A (fr)
CA (1) CA2361936C (fr)
CZ (1) CZ20012446A3 (fr)
DE (1) DE60022735T2 (fr)
HU (1) HU229441B1 (fr)
IL (2) IL144028A0 (fr)
MX (1) MXPA01006876A (fr)
NO (1) NO20013230L (fr)
NZ (1) NZ512628A (fr)
PL (1) PL349773A1 (fr)
SK (1) SK287112B6 (fr)
TR (1) TR200101943T2 (fr)
WO (1) WO2000040228A2 (fr)
ZA (1) ZA200105556B (fr)

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
JP2004508851A (ja) * 2000-06-22 2004-03-25 スリーエム　イノベイティブ　プロパティズ　カンパニー 粘膜表面を治療するためのシステムおよび方法
JP2002145777A (ja) * 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US20060142202A1 (en) * 2000-12-08 2006-06-29 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
WO2002092070A1 (fr) * 2001-05-11 2002-11-21 Elan Corporation, Plc Sels d'acide isostearique utilises comme accelerateurs de permeation
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
CA2458876A1 (fr) * 2001-08-30 2003-03-13 3M Innovative Properties Company Procedes de maturation de cellules dendritiques plasmocytoides au moyen de molecules modifiant les reponses immunitaires
AU2002343728A1 (en) * 2001-11-16 2003-06-10 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor pathways
AU2002364897A1 (en) * 2001-11-17 2003-06-10 Maria Martinez-Colon Imiquimod therapies
RU2327460C2 (ru) * 2001-11-29 2008-06-27 3М Инновейтив Пропертиз Компани Фармацевтические составы, содержащие иммуномодулятор
CA2365732A1 (fr) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Etalonnages
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US20040009212A1 (en) * 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
NZ534566A (en) * 2002-02-22 2007-02-23 3M Innovative Properties Co Method of reducing and treating UVB-induced immunosuppression
DK1487485T3 (da) * 2002-03-19 2011-03-14 Powderject Res Ltd Imidazoquinolinadjuvanser til DNA-vacciner
ATE420658T1 (de) * 2002-03-19 2009-01-15 Powderject Res Ltd Imidazoquinolinamine als adjuvantien für hiv dna vakzine
DE50308334D1 (de) * 2002-05-07 2007-11-22 Schott Ag Beleuchtungseinrichtung für Schaltflächen
MXPA04012199A (es) 2002-06-07 2005-02-25 3M Innovative Properties Co Imidazopiridinas sustituidas con eter.
NZ538812A (en) * 2002-08-15 2009-02-28 3M Innovative Properties Co Immunostimulatory compositions and methods of stimulating an immune response
US20040033968A1 (en) * 2002-08-16 2004-02-19 Lin Shun Y. Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
JP2006503068A (ja) * 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
MXPA05006740A (es) 2002-12-20 2005-10-05 3M Innovative Properties Co Imidazoquinolinas arilo-sustituidas.
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
US20060183767A1 (en) * 2003-01-06 2006-08-17 Eugene Mandrea Methods of stimulating immune response in certain individuals
US20040136917A1 (en) * 2003-01-06 2004-07-15 Eugene Mandrea Methods of stimulating immune response in virally infected individuals
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
MY140539A (en) * 2003-03-07 2009-12-31 3M Innovative Properties Co 1-amino 1h-imidazoquinolines
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
CA2518082C (fr) * 2003-03-13 2013-02-12 3M Innovative Properties Company Methodes de diagnostic de lesions de la peau
MXPA05009694A (es) * 2003-03-13 2005-10-20 3M Innovative Properties Co Metodos para mejorar la calidad de la piel.
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
JP2007514644A (ja) * 2003-04-10 2007-06-07 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応を向上させる方法および組成物
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
AU2004244962A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
WO2004110992A2 (fr) * 2003-06-06 2004-12-23 3M Innovative Properties Company Procede de preparation d'imidazo[4,5-c]pyridin-4-amines
US6943255B2 (en) * 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
US7521459B2 (en) 2003-07-28 2009-04-21 Metabeauty Inc. Method for treating damaged skin
RU2006102188A (ru) * 2003-07-31 2006-07-10 ЗМ Инновейтив Пропертиз Компани (US) Биоактивные композиции, включающие триазины
CA2534625A1 (fr) * 2003-08-05 2005-02-24 3M Innovative Properties Company Prophylaxie infectieuse utilisant des composes modifiant une reponse immune
BRPI0413558A (pt) * 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
EP2939693A1 (fr) * 2003-08-14 2015-11-04 3M Innovative Properties Company Modificateurs de réponse immunitaire modifiée par un lipide
WO2005020912A2 (fr) * 2003-08-25 2005-03-10 3M Innovative Properties Company Administration de composes modificateurs de la reponse immunitaire
AU2004266162A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
MXPA06002199A (es) 2003-08-27 2006-05-22 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi.
JP2007504172A (ja) * 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 粘膜に関連した症状の処置に関する方法
CA2537763A1 (fr) * 2003-09-05 2005-03-17 3M Innovative Properties Company Traitement pour le lymphome a cellules b cd5<sp>+</sp>
CA2540541C (fr) 2003-10-03 2012-03-27 3M Innovative Properties Company Imidazoquinolines a substitution alcoxy
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
TW200526656A (en) 2003-10-03 2005-08-16 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
EP1680080A4 (fr) * 2003-10-31 2007-10-31 3M Innovative Properties Co Activation des neutrophiles par des composes modificateurs de la reponse immunitaire
US7897767B2 (en) * 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
WO2005048945A2 (fr) 2003-11-14 2005-06-02 3M Innovative Properties Company Composes d'un anneau d'imidazo substitue par hydroxylamine
KR20070005550A (ko) 2003-11-17 2007-01-10 바이오마린 파머수티컬 인크. 대사 장애 치료를 위한 조성물 및 방법
AU2004293096A1 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2005051317A2 (fr) 2003-11-25 2005-06-09 3M Innovative Properties Company Systèmes cycliques d'imidazo substitués et procédés
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US7939526B2 (en) * 2003-12-04 2011-05-10 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
JP2007530450A (ja) * 2003-12-29 2007-11-01 スリーエム イノベイティブ プロパティズ カンパニー ピペラジン、［１，４］ジアゼパン、［１，４］ジアゾカン、および［１，５］ジアゾカン縮合イミダゾ環化合物
JP2007517055A (ja) * 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答の増強
EP1699788A2 (fr) 2003-12-30 2006-09-13 3M Innovative Properties Company Sulfonamides d'imidazoquinolinyle, d'imidazopyridinyle et d'imidazonaphtyridinyle
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
ES2665342T3 (es) * 2004-03-15 2018-04-25 Meda Ab Formulaciones y métodos para modificadores de la respuesta inmune
WO2005094531A2 (fr) 2004-03-24 2005-10-13 3M Innovative Properties Company Imidazopyridines, imidazoquinolines, et imidazonaphthyridines a substitution amide
EP1735010A4 (fr) * 2004-04-09 2008-08-27 3M Innovative Properties Co Methodes, compositions et preparations pour administration de modificateurs de reponse immunitaire (irm)
CA2564855A1 (fr) * 2004-04-28 2005-10-28 3M Innovative Properties Company Compositions et methodes pour vaccination muqueuse
US20050244502A1 (en) * 2004-04-28 2005-11-03 Mathias Neil R Composition for enhancing absorption of a drug and method
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7897609B2 (en) 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
CA2571360C (fr) * 2004-06-18 2014-11-25 3M Innovative Properties Company Imidazoquinolines, imidazopyridines et imidazonaphtyridines substituees utiles pour induire la biosynthese de cytokine chez des animaux
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006026470A2 (fr) * 2004-08-27 2006-03-09 3M Innovative Properties Company Compositions immunostimulatrices contre le vih
ATE555786T1 (de) * 2004-09-02 2012-05-15 3M Innovative Properties Co 1-alkoxy 1h-imidazo-ringsysteme und verfahren
WO2006029115A2 (fr) 2004-09-02 2006-03-16 3M Innovative Properties Company Systemes cycliques de 2-amino 1h-imidazo et procedes correspondants
WO2006029223A2 (fr) * 2004-09-08 2006-03-16 Children's Medical Center Corporation Methode de stimulation de la reponse immunitaire chez des nouveau-nes
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1804583A4 (fr) * 2004-10-08 2009-05-20 3M Innovative Properties Co Adjuvant pour vaccin a adn
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006055511A2 (fr) * 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Formule stable de comprimes
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
CA2594253C (fr) 2004-12-30 2015-08-11 3M Innovative Properties Company Traitement de metastases cutanees
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006073939A2 (fr) * 2004-12-30 2006-07-13 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphtyridin-4-amine ethanesulfonate et 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphtyridin-4-amine methanesulfonate
WO2006084251A2 (fr) * 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Formulations des gel aqueux contenant des modificateurs de reponse immunitaire
AU2006210587A1 (en) * 2005-02-04 2006-08-10 Takeda Pharmaceutical Company Limited Aqueous gel formulations containing 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
ES2475728T3 (es) 2005-02-09 2014-07-11 3M Innovative Properties Company Tiazoloquinolinas y tiazolonaftiridinas sustituidas con alcoxi
CA2597446A1 (fr) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Imidazoquinolines et imidazonaphthyridines substituees
CA2597587A1 (fr) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Composes cycliques imidazo[4,5-c] substitues par oxime et hydroxylamine et procedes associes
US8343993B2 (en) 2005-02-23 2013-01-01 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
CA2598656A1 (fr) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Composes d'imidazoquinolines a substitution hydroxyalkyle et procedes
WO2006091647A2 (fr) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Methode d'induction preferentielle de la biosynthese d'interferon
CA2598695A1 (fr) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Imidazoquinolines a substitution hydroxyalkyle
US8354424B2 (en) 2005-03-14 2013-01-15 Medicis Pharmaceutical Corporation Method of treating actinic keratosis
JP2008538550A (ja) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ，インコーポレイテッド ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物
JP2008535832A (ja) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ピラゾロピリジン−１，４−ジアミン、およびそのアナログ
JP2008539252A (ja) * 2005-04-25 2008-11-13 スリーエム イノベイティブ プロパティズ カンパニー 免疫活性化組成物
DE602006021408D1 (de) 2005-04-27 2011-06-01 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
EA200800782A1 (ru) 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
US20070081962A1 (en) * 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
KR20080083270A (ko) 2005-11-04 2008-09-17 콜레이 파마시티컬 그룹, 인코포레이티드 하이드록시 및 알콕시 치환된 1에이치 이미다조퀴놀린 및방법
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
EP1988896A4 (fr) 2006-02-22 2011-07-27 3M Innovative Properties Co Conjugués du modificateur de réponse immune
US8088788B2 (en) 2006-03-15 2012-01-03 3M Innovative Properties Company Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
WO2007106854A2 (fr) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. 1h-imidazonaphthyridines hydroxy et alcoxy substituées, et procédés associés
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
EP2029597A4 (fr) 2006-05-31 2011-11-23 Univ California Analogues de la purine
WO2007150030A2 (fr) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Synthèse microfluidique de nanoparticules organiques
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US20100092401A1 (en) * 2006-07-18 2010-04-15 Graceway Pharmaceuticals, Llc Immune response modifier formulations
US8124096B2 (en) * 2006-07-31 2012-02-28 3M Innovative Properties Company Immune response modifier compositions and methods
US20100144845A1 (en) * 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
WO2008030511A2 (fr) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. 3, 4, 6, 7-tétrahydro-5h-1, 2a, 4a, 8-tétraazacyclopenta[cd]phénalènes substitués
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US7666160B2 (en) * 2006-12-29 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery device
ES2552471T3 (es) 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124632A1 (fr) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Nanoparticules assistées par des composés amphiphiles pour délivrance ciblée
EP2630966B1 (fr) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Nano-technologie de vaccin
JP2011502474A (ja) * 2007-11-02 2011-01-27 クネーベル ドーベリッツ， マグナス フォン 上皮細胞におけるヒトパピローマウイルスゲノムの特異的なメチル化に関連する化合物および方法
MX2010007410A (es) * 2008-01-15 2011-02-25 Dow Pharmaceutical Sciences Formulacion de imiquimod.
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
US20100160368A1 (en) * 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US9662481B2 (en) 2008-10-07 2017-05-30 Cristcot Llc Method and apparatus for inserting a rectal suppository
US8192393B2 (en) 2008-10-07 2012-06-05 Christcot Medical Company Method and apparatus for inserting a rectal suppository
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2010080345A1 (fr) 2008-12-19 2010-07-15 Graceway Pharmaceuticals, Llc Formulations d'imiquimode à faible force de dosage et schémas posologiques courts pour traiter la kératose actinique
WO2010088924A1 (fr) 2009-02-06 2010-08-12 Telormedix Sa Compositions pharmaceutiques comprenant des imidazoquinolines (amines) et des dérivés de celles-ci appropriés pour une administration locale
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
EA025993B1 (ru) 2009-07-13 2017-02-28 Медисис Фармасьютикал Корпорейшн Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
ES2617451T3 (es) 2010-08-17 2017-06-19 3M Innovative Properties Company Composiciones lipidadas de compuestos modificadores de la respuesta inmunitaria, formulaciones, y métodos
WO2012061717A1 (fr) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Composés nicotiniques modifiés et procédés associés
EP3153180A1 (fr) 2011-06-03 2017-04-12 3M Innovative Properties Company Lieurs hétérobifonctionnels avec segments de polyéthylène glycol et conjugués de modificateur de réponse immunitaire fabriqués à partir de ceux-ci
WO2012167088A1 (fr) 2011-06-03 2012-12-06 3M Innovative Properties Company Lieurs hétérobifonctionnels comportant de segments de polyéthylène glycol et conjugués modificateurs de réponse immunitaire obtenus à partir de ceux-ci
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CA2871490C (fr) 2012-04-27 2022-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'oligonucleotides cpg co-formules avec un antibiotique pour accelerer la cicatrisation des plaies
AU2013255511B2 (en) 2012-05-04 2016-01-28 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
JP2015533306A (ja) 2012-10-19 2015-11-24 クリストコット インク 坐薬挿入デバイス、坐薬、および坐薬を製造する方法
WO2017197100A1 (fr) 2016-05-12 2017-11-16 Cristcot Llc Dispositif à usage unique d'insertion de suppositoire et procédé associé
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
BR112019024177A2 (pt) 2017-05-19 2020-06-02 Superb Wisdom Limited Derivados de resiquimode
EP3728255B1 (fr) 2017-12-20 2022-01-26 3M Innovative Properties Company Composés imidazo [4,5-c]quinoléine à substitution amide ayant un groupe de liaison à chaîne ramifiée destinés à être utilisés en tant que modificateur de la réponse immunitaire

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US3384541A (en) * 1964-10-28 1968-05-21 William G. Clark Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants
US3917624A (en) 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
IL92537A (en) * 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
DK0553202T3 (da) 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
EP0708772B1 (fr) 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5585612A (en) 1995-03-20 1996-12-17 Harp Enterprises, Inc. Method and apparatus for voting
JPH09208584A (ja) 1996-01-29 1997-08-12 Terumo Corp アミド誘導体、およびそれを含有する医薬製剤、および合成中間体
CA2253971A1 (fr) * 1996-05-09 1997-11-13 Pharma Pacific Pty.Ltd. Utilisation de forte dose d'interferon par contact des voies muqueuses pour traiter les infections virales et conditions neoplasiques
EP0906307B1 (fr) * 1996-06-10 2005-04-27 Merck & Co., Inc. Imidazoles substitues inhibant la cytokine
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
EP0894797A4 (fr) 1997-01-09 2001-08-16 Terumo Corp Nouveaux derives d'amide et intermediaires utilises pour leur synthese
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体

Also Published As

Publication number Publication date
EP1140091A2 (fr) 2001-10-10
DE60022735T2 (de) 2006-07-06
WO2000040228A2 (fr) 2000-07-13
AU2721600A (en) 2000-07-24
IL144028A (en) 2006-07-05
WO2000040228A3 (fr) 2001-04-05
US6245776B1 (en) 2001-06-12
PL349773A1 (en) 2002-09-09
IL144028A0 (en) 2002-04-21
CA2361936C (fr) 2009-06-16
NO20013230D0 (no) 2001-06-27
ATE304852T1 (de) 2005-10-15
MXPA01006876A (es) 2002-04-24
HUP0200329A3 (en) 2004-03-29
SK9542001A3 (en) 2001-12-03
HUP0200329A2 (hu) 2002-07-29
AU776654B2 (en) 2004-09-16
TR200101943T2 (tr) 2002-04-22
CA2361936A1 (fr) 2000-07-13
BR0007435A (pt) 2001-12-04
NZ512628A (en) 2004-03-26
KR20010101420A (ko) 2001-11-14
DE60022735D1 (de) 2006-02-02
CZ20012446A3 (cs) 2002-01-16
HU229441B1 (en) 2013-12-30
ZA200105556B (en) 2002-10-07
JP2002534377A (ja) 2002-10-15
CN1555264A (zh) 2004-12-15
EP1140091B1 (fr) 2005-09-21
NO20013230L (no) 2001-09-10

Similar Documents

Publication Publication Date Title
SK287112B6 (sk) Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
US6486168B1 (en) Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6706728B2 (en) Systems and methods for treating a mucosal surface
EP1495758A2 (fr) Formulations et procédés utilisés pour le traitement des états pathologiques des muqueuses au moyen d&#39;un modificateur de la réponse immunitaire
JP4447914B2 (ja) 免疫応答調節物質を含む医薬品
EP1844201B1 (fr) Formulations des gel aqueux contenant des modificateurs de reponse immunitaire
MXPA06002408A (es) Metodos relacionados al tratamiento de condiciones asociadas a la mucosa.
NZ583456A (en) Use of niacin based anhydrous compositions suitable for enhancing sexual wellness
CZ20024175A3 (cs) Systémy a způsoby pro léčbu slizničního povrchu
KR102666078B1 (ko) 항바이러스성 화합물을 포함하는 질내 적용 가능한 장치
RU2349321C2 (ru) Системы и способы лечения поверхности слизистых оболочек
AU2006252154A1 (en) Systems and methods for treating a mucosal surface
JP2008530014A (ja) １−（２−メチルプロピル）−１Ｈ−イミダゾ［４，５−ｃ］［１，５］ナフチリジン−４−アミンを含む水性ゲル製剤

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20190107